278 related articles for article (PubMed ID: 35641205)
21. Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment.
Nolla K; Benjamin DJ; Cella D
Nat Rev Urol; 2023 Jul; 20(7):420-433. PubMed ID: 36928615
[TBL] [Abstract][Full Text] [Related]
22. Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Chen YW; Rini BI
Curr Oncol Rep; 2022 Jun; 24(6):695-702. PubMed ID: 35247142
[TBL] [Abstract][Full Text] [Related]
23. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.
Cao G; Wu X; Wang Z; Tian X; Zhang C; Wu X; Zhang H; Jing G; Yan T
BMJ Open; 2020 Aug; 10(8):e034626. PubMed ID: 32859659
[TBL] [Abstract][Full Text] [Related]
24. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
25. Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma.
Spisarová M; Melichar B; Vitásková D; Študentová H
Future Oncol; 2021 Jan; 17(3):241-254. PubMed ID: 33016119
[TBL] [Abstract][Full Text] [Related]
26. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.
Spisarová M; Melichar B; Vitásková D; Študentová H
Expert Rev Anticancer Ther; 2021 Jul; 21(7):693-703. PubMed ID: 33794744
[No Abstract] [Full Text] [Related]
27. A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma.
Shay R; Nicklawsky A; Gao D; Lam ET
Clin Genitourin Cancer; 2021 Aug; 19(4):370-370.e7. PubMed ID: 33674224
[TBL] [Abstract][Full Text] [Related]
28. Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis.
Massari F; Mollica V; Rizzo A; Cosmai L; Rizzo M; Porta C
Expert Opin Drug Saf; 2020 Oct; 19(10):1329-1338. PubMed ID: 32799582
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma.
Flippot R; Gorgeu V; Pujalte M; Colomba E; Alves C; Cerbone L; Carril L; Derosa L; Escudier B; Albigès L
Bull Cancer; 2022 May; 109(2S):2S31-2S38. PubMed ID: 35760468
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Missed Opportunity.
Chadha J; Adashek JJ; Jim H; Kim Y; Semaan A; Chakiryan NH; Safa H; Hajiran A; Sexton W; Gilbert SM; Manley BJ; Spiess PE; Chahoud J
Clin Genitourin Cancer; 2022 Apr; 20(2):e158-e165. PubMed ID: 34974985
[TBL] [Abstract][Full Text] [Related]
31. IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time.
Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Panunzio A; Tappero S; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Antonelli A; Kosiba M; Kluth LA; Becker A; Chun FKH; Karakiewicz PI
Semin Oncol; 2022 Oct; 49(5):394-399. PubMed ID: 36333148
[TBL] [Abstract][Full Text] [Related]
32. Optimization of first-line systemic therapy in patients with advanced clear cell renal cell carcinoma.
Takagi T
Int J Urol; 2023 Sep; 30(9):705-713. PubMed ID: 36479730
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective.
Yoo M; Nelson RE; Cutshall Z; Dougherty M; Kohli M
JCO Oncol Pract; 2023 Mar; 19(3):e449-e456. PubMed ID: 36599117
[TBL] [Abstract][Full Text] [Related]
34. Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient.
Borchiellini D; Maillet D
Bull Cancer; 2022 May; 109(2S):2S4-2S18. PubMed ID: 35760470
[TBL] [Abstract][Full Text] [Related]
35. BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials.
Liu K; Huang Y; Xu Y; Wang G; Cai S; Zhang X; Shi T
Cancer Immunol Immunother; 2023 Aug; 72(8):2557-2572. PubMed ID: 37046008
[TBL] [Abstract][Full Text] [Related]
36. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
37. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.
Cetin B; Wabl CA; Gumusay O
Curr Treat Options Oncol; 2022 Apr; 23(4):609-629. PubMed ID: 35316480
[TBL] [Abstract][Full Text] [Related]
38. Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date.
Chau V; Bilusic M
Cancer Manag Res; 2020; 12():7321-7330. PubMed ID: 32884346
[TBL] [Abstract][Full Text] [Related]
39. A Podcast Discussion on the Current Treatment Landscape for Renal Cell Carcinoma.
Ivanyi P; Wiegmann JP; Eggers H; Grünwald V
Adv Ther; 2023 Sep; 40(9):3610-3619. PubMed ID: 37434067
[TBL] [Abstract][Full Text] [Related]
40. Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis.
Wang J; Li X; Wu X; Wang Z; Zhang C; Cao G; Zhang X; Peng F; Yan T
EBioMedicine; 2019 Sep; 47():78-88. PubMed ID: 31439476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]